{"groups":[{"description":"Patients receive bendamustine hydrochloride IV over 30 minutes on days 1 and 2; bortezomib SC on days 1, 8, 15, and 22; and dexamethasone PO on days 1, 8, 15, and 22. Treatment repeats every 35 days for 4 courses in the absence of disease progression or unacceptable toxicity. Patients achieving less than a VGPR or with more than 10% bone marrow plasmacytosis may receive 2 additional courses.\n\nBendamustine hydrochloride: Given IV\n\nBortezomib: Given SC\n\nDexamethasone: Given PO","id":"FG000","title":"Bendamustine, Bortezomib, Dexamethasone (Standard)"}],"periods":[{"milestones":[{"achievements":[{"groupId":"FG000","numSubjects":"24"}],"type":"STARTED"},{"achievements":[{"groupId":"FG000","numSubjects":"24"}],"type":"COMPLETED"},{"achievements":[{"groupId":"FG000","numSubjects":"0"}],"type":"NOT COMPLETED"}],"title":"Overall Study"}]}